Animal Models and Pharmacokinetics

  • G. E. Mawer
Part of the Chemotherapy book series (CT, volume 2)


Experimental models of human infections may help us to design treatment schedules which make more effective use of available antibacterial drugs. At the present time we determine the minimum inhibitory concentration of an antibiotic against a particular organism under conditions of steady antibiotic concentration. Yet in the treated patient the antibiotic concentration is never steady. Practical treatment schedules almost invariably involve a series of doses repeated at intervals of several hours. After each dose the concentration of antibiotic in the body fluids rises, reaches a more or less transient peak and then falls to a trough value immediately before or shortly after the next dose. We do not know how to relate the in vitro inhibitory concentration to this continuously changing antibiotic concentration in vivo.


Half Time Antibiotic Concentration Aminoglycoside Antibiotic Kidney Tubule Bacteriological Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brummett, R.E., Himes, D., Saine, B. & Vernon, J. A compara-t ive study of the ototoxicity of tobramycin and gentamicin. Arch. Otolaryng. 1972, 96, 505–512.PubMedCrossRefGoogle Scholar
  2. Burns, J.J. Prepared discussion. Proceedings of conference of non-human primate toxicology. Ed. Miller, Dept. of Health, Education and Welfare. Food and Drug Administration. Warrenton, Virginia. 1966, 66–68.Google Scholar
  3. De Rosa, F., Buoncristiani, U., Capitanucci, P. & Frongillo, R.F. Tobramycin; toxicological and pharmacological studies in animals and pharmacokinetic research in patients with varying degrees of renal impairment. Journal of international medical research. 1974, 2, 100.Google Scholar
  4. Fare, L.R., Actor, P., Sachs, C., Phillips, L., Joloza, Mac D., Pauls, J.F. & Weisbach, J.A. Comparative serum levels and protective activity of parenterally administered cephalosporins in experimental animals. Antimicrob. Ag. Chemother. 1974, 6, 150–155.CrossRefGoogle Scholar
  5. Gingell, J.C., Chisholm, G.D., Calnan, J.S. & Waterworth, P.M. The dose, distribution and excretion of gentamicin with special reference to renal failure. J. infect. Dis. 1969, 119, 396–401.PubMedCrossRefGoogle Scholar
  6. Heifetz, C.L., Chodubski, J.A., Pearson, I.A., Silverman, C.A. & Fisher, M.W. Butirosin compared with gentamicin in vitro and in vivo. Antimicrob. Ag. Chemother. 1974, 6, 124–134.CrossRefGoogle Scholar
  7. Hunt er, P.A., Rolinson, G.N. & Witting, D.A. Comparative activity of amoxycillin and ampicillin in an experimental bacterial infection in mice. Antimicrob. Ag. Chemother. 1973, 4, 285–293.CrossRefGoogle Scholar
  8. Noone, P., Parsons, T.M.C., Pattison, J.R., Slack, R.C.B., Garfield-Davies, D. & Hughes, K. Experience in monitoring gentamicin therapy during treat ment of serious Gram-negative sepsis. Brit. med. J. 1974, i, 477–481.Google Scholar
  9. Smith, C.C. Role of non-humanprimate in predicting metabolic disposition of drugs in man. Proceedings of conference on nonhuman primate toxicology. Ed. Miller. Dept. of Health, Education & Welfare. Food & Drug Administration, Warrenton, V irginia. 1966, 57–66.Google Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • G. E. Mawer
    • 1
  1. 1.University of ManchesterEngland

Personalised recommendations